IL5 and hypereosinophilic syndrome: Following this approach, our group developed a virus‐like particle (VLP)‐based therapeutic vaccine inducing IL‐5 autoantibodies (equine (e)IL‐5 coupled to cucumber mosaic virus‐like particles (CuMV) including a universal epitope of tetanus toxoid (TT), eIL‐5‐CuMVTT for treating equine hypereosinophilic diseases such as IBH).